08 dec: USA: Antallet af nytilmeldte ledige skuffer
08 dec: Bavarian: Ledelse får tegningsoptioner og ansatte incitamentsprog..
08-12-2016 15:01:36

Bavarian Nordic Introduces New Incentive Programs for Executive Management and Employees

Relateret indhold
26 jan - 
Bristol-Myers leverer svag indtjening og nedjusterer
17 jan - 
Tirsdagens aktier: Dong og Mærsk positive islæt i eller..
17 jan - 
Aktier/middag: Mærsk og Genmab i top mens markedet vent..
Relateret debat
11:43 - 
Den er begyndt at falde tilbage nu. Havde håbet på vi v..
11:37 - 
Måske den uforbeholdne anbefaling, fra alle tilstædevær..
11:11 - 
Der skal stærke hoveder til at præstere så dybdegående ..

COPENHAGEN, Denmark, December 8, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the board has decided to issue warrants to executive management and certain employees in the Bavarian Nordic Group. The decision is made in accordance with the shareholder authorization for the board of directors adopted as Article 5b of the Articles of Association and the Company's guidelines regarding incentive programs.

The warrant program entails the issuance of 450,300 warrants in total which entitle the warrant holders to subscribe for up to 450,300 shares in total with a nominal value of DKK 10 each at an exercise price of DKK 260.2 per share. The warrants may be exercised wholly or partly during eight fixed subscription periods during 2020 and 2021.

The value of each warrant equals DKK 54.2 and is calculated on the Black-Scholes model with a risk-free interest rate of -0.48 per cent and on the historical volatility of the shares. The calculation is based on a share price of DKK 222.5.

Furthermore, the Company introduces a three year incentive program in January 2017 for certain employees in the Bavarian Nordic Group. The program is a cash bonus program based on the development in the Company's share price. The incentive program will not have a dilutive effect on the shareholders.

Each employee participating in the program is awarded so-called phantom shares every month of employment until 31 December 2019. The exercise price is DKK 260.2. The phantom shares may be exercised in January 2020, only if the Company's share price by then exceeds the exercise price by at least DKK 5. In that case, each phantom share will yield a cash bonus equivalent to DKK 1 per point the share price exceeds the exercise price.

Based on the current number of employees in the Group eligible for participating in the program, the program will comprise up to 58,032 phantom shares. Executive management and other employees receiving warrants will not participate in the program. The average value of each phantom share granted equals DKK 37.9 calculated on the basis of the Black-Scholes model with a risk-free interest rate of -0.48 per cent and on the historical volatility of the shares. The calculation is based on a share price of DKK 222.5.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

Company Announcement no. 31 / 2016

2016-31-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 774102.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
22 feb
BAVA
Tak for den dybe analyse, meget brugbart. Jeg har fluks solgt 8400 stk. på din fine anbefaling.   Af..
20
20 feb
BAVA
Der er såmænd nok ikke så mange herinde, der har en profession, der gør os til eskperter - og da sle..
14
23 feb
BAVA
Han havde nok påbegyndt tråden inden de 2 andre var oprettet,..det er jo trods alt noget af en tekst..
9
20 feb
BAVA
  Jeg syntes det mdr for mdr ser bedre og bedre ud - markedet har en lidt anden mening - h..
8
22 feb
BAVA
6
21 feb
BAVA
Jeg vil heller være konservativ i det jeg tror - men kik lige selv på den pipeline på det som kommer..
6
19 feb
BAVA
Jeg ligger lang og er igen virkelig tanket i Bava, men vil alligevel nævne at der er andre Biotech d..
5
23 feb
BAVA
Lad os nu lige se om der er nogle af analytikkerne som reagere på dette - fordelen ved RSV er at res..
4
23 feb
BAVA
Published: 16:20 CET 23-02-2017 /GlobeNewswire /Source: Bavarian Nordic A/S / : BAVA /ISIN: DK001599..
4
22 feb
BAVA
Der kom jo intet viden ud af denne diskussion er I alle daytradere? Den 15/3 kommer der regnskab ..
4

Aktier/middag: Mærsk og Genmab i C20-bunden og dukkert til Rockwool

24-02-2017 11:44:51
Trods yderligere fremgang til ISS, der torsdag leverede et stærkt regnskab, ligger det danske aktiemarked fredag middag i et minus efter fald i aktier som Mærsk..

Aktier/tendens: Rockwool-tal og analytikerændringer sætter retningen

24-02-2017 08:32:38
Der er udsigt til en rolig start på fredagens danske aktiehandel, hvor regnskaber fra en stribe mellemstore selskaber vil tage opmærksomhed og være med til at s..

Genmab-boss' aktiepost krydser 1,5 mia. kr. efter rekordregnskab

23-02-2017 16:10:14
Genmab har de seneste år været en gylden investering for selskabets aktionærer, men ingen enkeltpersoner har formentlig tjent så mange penge på aktiekursens him..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Genmab-boss' aktiepost krydser 1,5 mia. kr. efter rekordregnskab
2
Genmab/SEB: Giver en af de få forsigtige anbefalinger
3
Vestas-rival viser stor fremgang over hele linjen
4
Aktier/tendens: Rockwool-tal og analytikerændringer sætter retningen
5
Torsdagens aktier: Fald til C20 trods plusser til WDH og Genmab

Relaterede aktiekurser

Bavarian Nordic A/S 283,50 1,3% Stigning i aktiekurs
Bavarian Nordic DKK10 39,70 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. februar 2017 13:45:27
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170217.2 - EUROWEB2 - 2017-02-24 13:45:27 - 2017-02-24 13:45:27 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x